Skip to content

Effects of High Intensity Inspiratory Muscle Training on Exercise Capacity in Patients With Bronchiectasis

Effects of High Intensity Inspiratory Muscle Training on Exercise Capacity in Patients With Bronchiectasis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02656992
Enrollment
45
Registered
2016-01-15
Start date
2014-09-30
Completion date
2018-01-05
Last updated
2018-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchiectasis

Keywords

Bronchiectasis, High-intensity inspiratory muscle training

Brief summary

Reduced exercise tolerance is commonly reported in patients with bronchiectasis. The purpose of this study is to evaluate the effects of high-intensity inspiratory muscle training (High-IMT) and sham High-IMT (control) on exercise capacity, respiratory muscle function (strength and endurance) and health related quality of life in patients with bronchiectasis.

Detailed description

Bronchiectasis often demonstrates decreased exercise tolerance, marked dyspnea and fatigue. The causes are multifactorial and include altered pulmonary mechanics, inefficient gas exchange, decreased muscle mass, and psychological status, which all lead to a progressive detraining effect. Essentially both the pathology and the functional manifestations of bronchiectasis increase the demand for inspiratory muscle work and that contribute to dyspnea and exercise limitation. In recent studies reduced strength of respiratory muscles are investigated in bronchiectasis and can be contribute the exercise limitation. Additionally IMT has shown to improve respiratory muscle function, exercise tolerance and dyspnea in patients with bronchiectasis. Despite this, the number of studies are inadequate and so the optimal training protocol remains still to be defined. In this study the researchers want to investigate the effects of high-intensity inspiratory muscle training in functional results in patients with bronchiectasis.

Interventions

Sponsors

Hacettepe University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* diagnosis of bronchiectasis with high resolution computed tomography * being 18-65 years of age * being able to walk and co-operate

Exclusion criteria

* acute exacerbation or change in drugs or usage of antibiotics in last 3 weeks * neurological disease, severe orthopaedic problem or advanced heart failure

Design outcomes

Primary

MeasureTime frameDescription
Exercise capacity using incremental shuttle walk test and 6-minute walk testBaseline to 8 weeks* The incremental shuttle walk test will be performed in an enclosed corridor. Patients are required to walk back and forth, turning around two cones placed 9 meters apart making the shuttle distance 10 meters long. Patients will follow the rhythm dictated by the audio signal. * 6-minute walk test will be performed in a long, straight, enclosed corridor 30 meters in length. Patients are required to walk in their walking speed with standardised instructions. The distance walked by subjects during 6 minutes will be recorded.

Secondary

MeasureTime frameDescription
Respiratory muscle enduranceBaseline to 8 weeksRespiratory muscle endurance is assessed with constant and progressive loading protocols which subjects breathe against threshold loads.
Health related quality of life is assessed with Leicester Cough QuestionnaireBaseline to 8 weeks
Respiratory muscle strengthBaseline to 8 weeksRespiratory muscle strength is measured through maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) using a handheld device.
Fatigue severity is assessed with Fatigue Severity IndexBaseline to 8 weeks
Severity of disease is assessed with Bronchiectasis Severity IndexBaseline to 8 weeks
Dyspnea severity is assessed with The Modified Medical Research Council Dyspnea Scale (MMRC)Baseline to 8 weeks

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026